Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
IL-33 (human) (rec.) (His)
155
CHF
CHF 155.00
In stock
AG-40A-0042-C01010 µgCHF 155.00
AG-40A-0042-C05050 µgCHF 470.00
Figure 1: Activation of a human ST2-dependent NF-κB pathway.
HEK-293 cells were transiently co-transfected with 500 ng of human ST2-containing vector (or empty vector as a negative control), a vector containing NF-κB-driven firefly luciferase, and a vector containing Renilla luciferase as a internal control in a 12-well plate. 40hr after transfection, cells were treated with IL33 (human) (rec.) (His) (Prod. No. AG-40A-0042) at the concentration as indicated for 8hr, followed by measurement with a dual luciferase assay.
HEK-293 cells were transiently co-transfected with 500 ng of human ST2-containing vector (or empty vector as a negative control), a vector containing NF-κB-driven firefly luciferase, and a vector containing Renilla luciferase as a internal control in a 12-well plate. 40hr after transfection, cells were treated with IL33 (human) (rec.) (His) (Prod. No. AG-40A-0042) at the concentration as indicated for 8hr, followed by measurement with a dual luciferase assay.
Figure 2: Pull down assay:
a) pull down of hIL-33-His by hST2-Fc
b) pull down of hST2-Fc by hIL-33-His
5μg of hST2-Fc (or control Fc protein), 2μg of hIL-33-His (Prod. No. AG-40A-0042) (or control His protein), and protein G resin (or anti-His resin) were incubated in 0.5ml RIPA buffer overnight at 4°C. The precipitates were separated by SDS-PAGE, electro-transferred onto NC membrane, and immunoblotted for the presence of hIL-33-His or hST2-Fc with anti-His HRP or anti-hIgG HRP, respectively.
a) pull down of hIL-33-His by hST2-Fc
b) pull down of hST2-Fc by hIL-33-His
5μg of hST2-Fc (or control Fc protein), 2μg of hIL-33-His (Prod. No. AG-40A-0042) (or control His protein), and protein G resin (or anti-His resin) were incubated in 0.5ml RIPA buffer overnight at 4°C. The precipitates were separated by SDS-PAGE, electro-transferred onto NC membrane, and immunoblotted for the presence of hIL-33-His or hST2-Fc with anti-His HRP or anti-hIgG HRP, respectively.
| Product Details | |
|---|---|
| Synonyms | Interleukin-33; IL-1F11; NF-HEV |
| Product Type | Protein |
| Properties | |
| Source/Host | E. coli |
| Sequence | Human IL-33 (aa 112-270) is fused at the C-terminus to a His-tag. |
| Crossreactivity | Human |
| Specificity | Binds to human ST2. |
| Biological Activity | Activates human ST2-dependent NF-κB pathway. |
| MW | ~18kDa (SDS-PAGE) |
| Purity | ≥90% (SDS-PAGE) |
| Endotoxin Content | <1EU/μg purified protein (LAL test; Lonza). |
| Concentration | 1mg/ml |
| Formulation | Liquid. 0.2μm-filtered solution in 55mM TRIS-Cl, pH 8.2, containing 150mM NaCl. |
| Other Product Data | UniProt link Q2YEJ5: Interleukin-33 (human) |
| Shipping and Handling | |
| Shipping | BLUE ICE |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice |
After opening, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles. For maximum product recovery after thawing, centrifuge the vial before opening the cap. |
| Use/Stability |
Stable for at least 6 months after receipt when stored at -20°C. Working aliquots are stable for up to 3 months when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
Interleukin-33 (IL-33; HF-NEV; IL-1F11), a member of the IL-1 family of cytokines, is expressed by many cell types following pro-inflammatory stimulation and is thought to be released on cell lysis. The 30kDa human IL33 is converted by CASP1 to a 18kDa protein. IL33 binds to and signals through ST2 (IL1R1) and its stimulation recruits MYD88, IRAK, IRAK4, and TRAF6, followed by phosphorylation of ERK1 (MAPK3)/ERK2 (MAPK1), p38 (MAPK14), and JNK. The ability of IL-33 to target numerous immune cell types, like Th2-like cells, mast cells, and B1 cells, and to induce cytokine and chemokine production underlines its potential in influencing the outcome of a wide range of diseases, such as arthritis, asthma, atopic allergy & anaphylaxis, cardiovascular disease/atherosclerosis, nervous system diseases, and sepsis.
Product References
- IL-33 can promote survival, adhesion and cytokine production in human mast cells: M. Iikura, et. al; Lab. Invest. 87, 971 (2007)
- Interleukin-33 enhances adhesion, CD11b expression and survival in human eosinophils: M. Suzukawa, et al.; Lab. Invest. 88, 1245 (2008)
- An IL-1 cytokine member, IL-33, induces human basophil activation via its ST2 receptor: M. Suzukawa, et al.; J. Immunol. 181, 5981 (2008)
- Tissue cytokine IL-33 modulates the cytotoxic CD8 T lymphocyte activity during nutrient deprivation by regulation of lineage-specific differentiation programs: C. Dreis, et al.; Front. Immunol. 10, 1698 (2019)
- Long-Acting IL-33 Mobilizes High-Quality Hematopoietic Stem and Progenitor Cells More Efficiently Than Granulocyte Colony-Stimulating Factor or AMD3100: C. Alt, et al.; Biol. Blood Marrow Transplant 25, 1475 (2019)
Related Products
